1976
Desmond-Hellmann notes Genentech was founded in 1976 and that she arrived almost 20 years later.
“And the fact was that Genentech was founded in 76. So I got there, you know, almost 20 years later.”
Topic
11 facts from 5 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
1976
Desmond-Hellmann notes Genentech was founded in 1976 and that she arrived almost 20 years later.
“And the fact was that Genentech was founded in 76. So I got there, you know, almost 20 years later.”
1980
In 1980 Genentech and Eli Lilly announced a partnership to produce human insulin using recombinant DNA, the first genetically engineered drug.
“in 1980, Genentech and Eli Lilly, as their partner, changed everything with recombinant DNA and genetic engineering of drugs.”
1980
Genentech raised $35 million in its 1980 initial public offering, which was considered an enormous amount at the time.
“Genentech, when it went public in 1980, 10 years earlier, it raised $35 million”
1995-2009
Sue Desmond-Hellmann worked at Genentech from 1995 to 2009, a period the host describes as its glory days as a developer of cancer drugs.
“She made her name in the biopharmaceutical industry at Genentech from 1995 to 2009, the glory days when it became the world's most important developer of new cancer drugs.”
1995
When Desmond-Hellmann joined in the mid-1990s, Genentech had three approved drugs: growth hormone, Activase and Pulmozyme, and no cancer drugs.
“Genentech had three approved drugs, growth hormone, Activase, and Pulmozyme.”
1997
Genentech's partnership with IDEC on Rituxan came around 1995 or 1996, and Rituxan was approved in 1997.
“There was not. The partnership came, I think, in 95, 96, because Rituxan was approved in 97.”
1998
Herceptin was approved in 1998, about a year after Rituxan.
“And then Herceptin came just a year later, I think, 98.”
2003
When he joined Genentech in 2003, Tessier-Lavigne oversaw about two-thirds of the research portfolio, including oncology.
“I was brought in to oversee about two-thirds of the research portfolio, including oncology”
Undated
Genentech's R&D head Art Levinson believed in leaving a job open rather than hiring a 'B minus', which made rapid growth harder.
“Art had this philosophy that if you couldn't find the right person for the job, you should just leave it open.”
Undated
Recursion signed a collaboration with Roche and Genentech lasting more than a decade, covering neuroscience and one oncology indication.
“In December, almost exactly a year ago, December last year, we signed a huge collaboration with Rosh and Genentech to deploy our technology in partnership with them for more than a decade”
Undated
Genentech, which had spun out its earlier neuroscience work, rebuilt a neurodegeneration research group during Tessier-Lavigne's tenure.
“So we actually built back up a neuro group at Genentech.”
Episodes